Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ClaimsFiler, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6 for that window.
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention ClaimsFiler, the most common co-covered peer. Their average consequence score of 5 runs below the beat's 6 for that window. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. We currently track 1 Biotech story that mention Kyndryl Holdings, Inc., all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kyndryl Holdings, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Anticipated Amended Complaint
Expected filing of detailed allegations following the appointment of lead plaintiffs.
Lead Plaintiff Deadline
Final date for eligible investors to file applications in the class action lawsuits against QURE and KD.
Legal Alert Issued
ClaimsFiler reminds shareholders of upcoming deadlines for lead plaintiff applications.
Investors in uniQure N.V. and Kyndryl Holdings have until April 13, 2026, to file as lead plaintiffs in securities class action lawsuits following significant stock losses. The litigation highlights increasing regulatory and disclosure pressures on biotech firms specializing in complex gene therapies.
Kyndryl Holdings, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
